These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 6333960

  • 1. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
    Corvetta A, Spaeth PJ, Ghirelli PA, Orecchioni F, Buetler R, Montroni M, Nydegger UE.
    Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of immune precipitation by complement.
    Hong K, Takata Y, Sayama K, Kozono H, Takeda J, Nakano Y, Kinoshita T, Inoue K.
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [Abstract] [Full Text] [Related]

  • 3. [Serum complement levels in patients with rheumatoid arthritis and vasculitis].
    Tomooka K.
    Fukuoka Igaku Zasshi; 1989 Oct; 80(10):456-66. PubMed ID: 2613159
    [Abstract] [Full Text] [Related]

  • 4. Polymeric IgA and IgA rheumatoid factor decrease the capacity of serum to solubilize circulating immune complexes in patients with primary IgA nephropathy.
    Schena PF, Pastore A, Sinico RA, Montinaro V, Fornasieri A.
    J Immunol; 1988 Jul 01; 141(1):125-30. PubMed ID: 3379302
    [Abstract] [Full Text] [Related]

  • 5. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G, Jonsson H, Sjöholm A, Sturfelt G, Svehag SE.
    J Clin Lab Immunol; 1988 Jun 01; 26(2):73-9. PubMed ID: 3264027
    [Abstract] [Full Text] [Related]

  • 6. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK, Hamilton AO, Yeung-Laiwah AC, Whaley K.
    Clin Exp Immunol; 1984 Nov 01; 58(2):486-92. PubMed ID: 6333948
    [Abstract] [Full Text] [Related]

  • 7. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera.
    Balestrieri G, Pagani D, Tincani A.
    J Clin Lab Immunol; 1983 Nov 01; 12(3):147-50. PubMed ID: 6663608
    [Abstract] [Full Text] [Related]

  • 8. Control of immune complexes by the classical pathway.
    Whaley K, Ahmed AE.
    Behring Inst Mitt; 1989 Jul 01; (84):111-20. PubMed ID: 2529842
    [Abstract] [Full Text] [Related]

  • 9. Reduced complement-mediated immune complex solubilization in leprosy patients.
    Ramanathan VD, Sharma P, Ramu G, Sengupta U.
    Clin Exp Immunol; 1985 Jun 01; 60(3):553-8. PubMed ID: 3874729
    [Abstract] [Full Text] [Related]

  • 10. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.
    Schifferli JA, Woo P, Peters DK.
    Clin Exp Immunol; 1982 Mar 01; 47(3):555-62. PubMed ID: 6979442
    [Abstract] [Full Text] [Related]

  • 11. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
    Wouters D, Wiessenberg HD, Hart M, Bruins P, Voskuyl A, Daha MR, Hack CE.
    J Immunol Methods; 2005 Mar 01; 298(1-2):35-45. PubMed ID: 15847795
    [Abstract] [Full Text] [Related]

  • 12. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ.
    J Immunol; 1986 May 01; 136(9):3378-83. PubMed ID: 3485688
    [Abstract] [Full Text] [Related]

  • 13. Immune complexes and complement profile in essential mixed cryoglobulinemia before and after plasma exchange.
    Corvetta A, Marchegiani G, Salvi A, Chirelli PA, Danieli G.
    Int J Artif Organs; 1983 Jul 01; 6 Suppl 1():65-8. PubMed ID: 6642740
    [Abstract] [Full Text] [Related]

  • 14. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
    Füst G, Czink E, Minh D, Miszlay Z, Varga L, Hollán SR.
    Clin Exp Immunol; 1985 Jun 01; 60(3):489-95. PubMed ID: 4017286
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of immune precipitation by complement.
    Schifferli JA, Bartolotti SR, Peters DK.
    Clin Exp Immunol; 1980 Nov 01; 42(2):387-94. PubMed ID: 6781802
    [Abstract] [Full Text] [Related]

  • 16. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
    Wouters D, Brouwer MC, Daha MR, Hack CE.
    Mol Immunol; 2008 Apr 01; 45(7):1893-9. PubMed ID: 18054386
    [Abstract] [Full Text] [Related]

  • 17. Immune complex modulation by plasma proteins. With special reference to the complement system and autoimmune diseases.
    Baatrup G.
    Dan Med Bull; 1989 Oct 01; 36(5):443-63. PubMed ID: 2530063
    [Abstract] [Full Text] [Related]

  • 18. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
    Kilgallon W, Amlot PL, Williams BD.
    Clin Exp Immunol; 1982 Jun 01; 48(3):705-14. PubMed ID: 6811171
    [Abstract] [Full Text] [Related]

  • 19. A study of in vivo immune complex formation and clearance in man.
    Davies KA, Hird V, Stewart S, Sivolapenko GB, Jose P, Epenetos AA, Walport MJ.
    J Immunol; 1990 Jun 15; 144(12):4613-20. PubMed ID: 2141040
    [Abstract] [Full Text] [Related]

  • 20. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P, Michaelsen TE, Aase A, Mollnes TE.
    J Immunol; 1990 Jan 01; 144(1):198-203. PubMed ID: 2295791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.